Novel Phosphatidylserine-Targeting Immuno-Biologicals for Cancer and Viral Treatment

PS-Targeting Biological inhibits tumor growth

Invention Summary:

Phosphatidylserine (PS) is a phospholipid that is restricted to the inner plasma membrane in healthy cells. In the past decade, the constitutive externalization of PS has been observed in a wide range of solid tumors, and is considered a global immunosuppressive signal akin to other checkpoint inhibitory signals in the tumor environment.

Rutgers scientists have developed a series of novel fusion proteins consisting of a PS-targeting domain and an immune-stimulating cytokine domain. The PS-targeting domain can target cancer cells with high specificity and block the PS signaling to suppress tumor growth and promote production of inflammatory cytokines at the tumor site. The cytokine domain can promote tumor recognition, inhibit tumor angiogenesis and induce immune-stimulatory activities of immune cells. In addition to the cancer treatment, these fusion molecules can also target virus-infected cells, suppress virus spread and enhance antiviral signaling, serving as wide spectrum antivirals. The purified fusion proteins have been tested in vitro for the antiviral activities and in vivo for anti-cancer activities.

In a tumor-bearing mouse model, it has been shown that the tumor growth was significantly inhibited by the fusion protein, along with the enhanced immunogenic signaling responses.

Market Applications:

  • Cancer Therapeutics
  • Antiviral Therapeutics
  • Research Tools


  • The anti-PS domain allows targeted site-specific drug delivery
  • Potentially higher efficacy due to synergistic effect by blockage of PS signaling and induction of cytokine specific activities

Intellectual Property & Development Status:

Patent pending. Available for licensing and/or research collaboration.

Rutgers ID: S2017-109
Life Sciences
Shan Wan
Senior Licensing Manager
(848) 932-4468
Sergei Kotenko
Viralkumar Davra
Raymond Birge